Total Worldwide Market for Antibiotics and Antifungals Was US$25 Billion in 2005, But Is Predicted To Fall To Between US$15 and US$20 Billion By 2016.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c46926) has announced the addition of The Global Market for AntiMicrobials and Antifungals; Challenging Resistance to 2015 to their offering. Antibiotic resistance antibiotic resistance, n the ability of certain strains of microorganisms to develop resistance to antibiotics. antibiotic resistance is a significant problem which is negatively impacting prescribing patterns, consequently reducing antibiotic usage. The total worldwide market for antibiotics and antifungals was US$25 billion in 2005, but is predicted to fall to between US$15 and US$20 billion by 2016. This forecast is based on a number of factors, but largely due to declining rates of antibiotic prescriptions for respiratory infections - a major segment of the market. Other contributing factors include the loss of market exclusivity for a number of popular branded antibiotics, including Abbott's Biaxin and Pfizer's Zithromax in 2005. Generic competitors of these drugs have already been launched and are set to make serious inroads inroads Noun, pl make inroads into to start affecting or reducing: my gambling has made great inroads into my savings inroads npl to make inroads into [+ on the branded market in the years to come. In this unique market analysis report from Spectra Intelligence, The Global Market for Antimicrobials and Antifungals: Challenging Resistance to 2016, the reader will be presented with a comprehensive asessment of the global market for anti-infectives and antifungals. Included in the analysis are therapeutics to combat the lethal microorganisms MRSA MRSA Methicillin-resistant Staphylococcus aureus. See MARSA. , C. difficile, and the highly infectious agents potentially used in bioterrorism. The report also provides current sales and prescription trends for antibiotics and antifungals and a detailed review of the current armamentarium ar·ma·men·tar·i·um n. pl. ar·ma·men·tar·i·ums or ar·ma·men·tar·i·a The complete equipment of a physician or medical institution, including drugs, books, supplies, and instruments. of marketed antibiotics and antifungals. Resistance mechanisms and efforts to target those mechanisms in drug discovery are also discussed. Furthermore, mechanisms of action of current and novel anti-infective therapeutics, side effects Side effects Effects of a proposed project on other parts of the firm. , and how differences in dosage formulations can affect their attractiveness to physicians and patients are also detailed. The report also provides an up-to-date extensive list of companies engaged in antibacterial antibacterial /an·ti·bac·te·ri·al/ (-bak-ter´e-al) destroying or suppressing growth or reproduction of bacteria; also, an agent that does this. an·ti·bac·te·ri·al adj. and antifungal drug An antifungal drug is medication used to treat fungal infections such as athlete's foot, ringworm, candidiasis (thrush), serious systemic infections such as cryptococcal meningitis, and others. Such drugs are usually obtained by a doctor's prescription or purchased over-the-counter. discovery and lists some of the novel scientific approaches being taken, including chemical biology Chemical biology is a scientific discipline spanning the fields of chemistry and biology that involves the application of chemical techniques and tools, often compounds produced through synthetic chemistry, to the study and manipulation of biological systems. , toxicogenomics, and computational approaches. It further documents efforts by companies to extend profits on drugs that are off-patent by developing new formulations with additional advantages benefiting patient compliance. Pipeline products and their advantages and disadvantages are also covered in-depth in the market analysis. Content Outline: List of Tables List of Figures List of Abbreviations Executive Summary Objective of the Report Research Methodology Chapter 1. Introduction To Antibiotics And Antifungals Chapter 2. Bacterial And Fungal Infections Fungal infections Several thousand species of fungi have been described, but fewer than 100 are routinely associated with invasive diseases of humans. And Diseases Chapter 3. Classic Antibiotics And Antifungals: Pipeline Insights Chapter 4. New Structures And/Or Novel Targets: Approved Or In The Pipeline Chapter 5. Theworldmarket for Anti-Infectives And Antifungals Chapter 6. Challenges In Developing Andmarketing New Antibiotics Chapter 7. Companies Marketing Or Developing Antimicrobials And Antifungals Some Companies Mentioned: Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. Achaogen Achillion Activbiotics Advanced Life Sciences Advancis Agilent Alpharx Arpida Ltd. Astrazeneca Bausch & Lomb BAyer Biovertis Centocor Ceragenix Pharmaceuticals  This article or section is written like an .Please help [ rewrite this article] from a neutral point of view. Mark blatant advertising for , using . Cerexa Chiron Cubist Pharmaceuticals Enanta Pharmaceuticals Genelogic GlaxoSmithKline Roche Inhibitex Intercell Johnson & Johnson Ketec Kyorin Merck Microcide Morphochem Nanostream Novartis Novexel Novozymes Oragenics Pfizer Polymedix Replidyne Sanofi-Aventis Schering-Plough Toyama Chemical Vertex Pharmaceuticals Vicuron Wyeth For more information visit http://www.researchandmarkets.com/reports/c46926 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion